How Is CIDP Different From ALS, CMT, MMN, and POEMS?

If your doctor is investigating whether you have chronic inflammatory demyelinating polyneuropathy (CIDP), they will likely run tests to rule out several “look-alike” conditions, including ALS, CMT, multifocal motor neuropathy (MMN), and POEMS syndrome. While these conditions all affect the nervous system and can cause overlapping symptoms like weakness and numbness ^[1], their underlying causes and treatments are drastically different. Accurate diagnosis ensures you receive effective therapy and avoids exposing you to expensive, potentially risky immune treatments that will not work for your specific condition ^[2].

Safety Warning: If you experience rapidly worsening weakness, trouble breathing or swallowing, sudden loss of the ability to walk, or repeated falls, seek urgent medical attention. Do not stop or change your prescribed treatments without consulting your neurologist.

How the Pieces Fit Together

Diagnosing CIDP and distinguishing it from its mimics requires a specialist to look at the entire puzzle. No single symptom, blood test, or nerve conduction result provides an automatic answer ^[3]. Doctors look at the pattern of weakness, whether sensory nerves are involved, the specific details of a nerve conduction study (NCS) and electromyogram (EMG), and specialized blood or genetic tests.

The patterns below are general diagnostic clues used by neurologists, not a checklist for self-diagnosis.

Amyotrophic Lateral Sclerosis (ALS)

ALS is a progressive neurodegenerative disease affecting motor neurons, whereas typical CIDP is an autoimmune condition targeting the protective myelin coating of peripheral nerves and nerve roots ^[4].

• Symptoms: CIDP typically causes symmetrical weakness in both the arms and legs, along with sensory loss (numbness or tingling) ^[4]. ALS, by contrast, typically does not cause sensory loss ^[5]. ALS often involves fasciculations (visible muscle twitching) and severe atrophy (muscle thinning and shrinking), though these symptoms are not exclusively unique to ALS ^[6].
• Neurological signs: Doctors check for upper-motor-neuron signs—such as muscle stiffness (spasticity) or overactive reflexes. If these are present alongside lower-motor-neuron signs, they strongly suggest a motor neuron disorder like ALS ^[5]. However, these signs may be absent early on, and reflexes can be reduced in ALS if muscle atrophy is severe.
• Testing: While nerve conduction studies (NCS) in CIDP show clear patterns of myelin damage (like conduction block or scattered slowing), the severe nerve-fiber loss in ALS can sometimes slow down nerve signals, occasionally mimicking some features of CIDP ^[7]. However, ALS usually lacks the marked demyelination and temporal dispersion seen in CIDP ^[7]. A careful clinical exam is crucial to tell them apart.

Charcot-Marie-Tooth Disease (CMT)

CMT is a group of inherited, genetic neuropathies, rather than an acquired immune condition like CIDP.

• Symptoms: CMT often begins in childhood or young adulthood and progresses very slowly ^[8]. It can cause skeletal deformities like pes cavus (very high foot arches), hammertoes, or spinal curvature ^[9].
• Family history: A family history of neuropathy strongly points to CMT, but sporadic cases occur, so a lack of family history does not rule it out ^[10].
• Testing: Some forms of CMT (such as CMT1A) meet the nerve-slowing thresholds used to diagnose CIDP ^[11]. However, CMT typically shows diffuse, uniform slowing across nerves, rather than the scattered, patchy slowing seen in acquired conditions like CIDP ^[11]. Genetic testing is supportive, but a negative genetic panel does not entirely exclude an inherited neuropathy ^[9].

Multifocal Motor Neuropathy (MMN)

MMN is an immune-mediated neuropathy that requires a completely different treatment strategy from CIDP.

• Symptoms: While typical CIDP causes symmetrical weakness in both proximal (closer to the body) and distal (further away) muscles, MMN usually causes asymmetrical weakness—meaning one hand or arm might be much weaker than the other ^[12]. Crucially, MMN is purely a motor condition; it does not cause the objective sensory loss typically seen in CIDP ^[12].
• Testing: NCS in MMN often shows conduction block—a substantial reduction in the electrical signal between stimulation sites on a motor nerve, usually outside of common compression sites like the wrist ^[13]. Blood tests may show anti-GM1 antibodies; this result supports an MMN diagnosis, but a negative test does not rule it out, and a positive test alone does not prove it ^[14].
• Treatment distinction: Identifying this mimic is vital because MMN is generally treated with intravenous immunoglobulin (IVIg), whereas corticosteroids and plasma exchange—which are highly effective for CIDP—are typically ineffective for MMN and steroids may even worsen MMN symptoms ^{[15] [16]}.

POEMS Syndrome

POEMS is a rare, complex, and potentially life-threatening blood and multi-system disorder. The acronym stands for Polyneuropathy, Organomegaly (enlarged organs), Endocrinopathy (hormone problems), Monoclonal protein, and Skin changes ^[17].

• Symptoms: Like CIDP, POEMS causes a demyelinating polyneuropathy, but it often involves severe, painful nerve damage heavily concentrated in the legs ^[18]. It is accompanied by systemic (whole-body) issues like fluid retention (edema), enlarged lymph nodes or liver/spleen, and skin thickening ^[17].
• Testing: Diagnosis requires a combination of findings, specifically a polyneuropathy and a monoclonal protein (an abnormal antibody produced by cloned plasma cells), plus other major or minor criteria ^[17]. Doctors may check the blood for VEGF (Vascular Endothelial Growth Factor) ^[19]. While elevated VEGF is a major criterion, it is not perfectly specific; imaging to look for sclerotic bone lesions and bone marrow evaluations are often part of a hematologist’s workup ^[20].

Anti-MAG Neuropathy

This condition is characterized by a slowly progressive neuropathy that is primarily sensory (causing numbness, tingling, and unsteadiness in walking) and typically starts in the hands and feet ^[21].

• Testing: Doctors look for a specific monoclonal protein (IgM) in the blood and test for anti-MAG antibodies ^[22]. A highly elevated antibody level, paired with the typical slow distal sensory pattern and an IgM monoclonal protein, points to anti-MAG neuropathy rather than typical CIDP ^{[22] [23]}. Low-level positive results can be nonspecific.

The Risks of Misdiagnosis

Because these diseases operate differently, their treatments differ drastically. ALS and CMT do not respond to immune therapies ^{[2] [8]}. POEMS requires targeted treatments directed at the underlying plasma-cell disorder ^[24]. MMN responds to IVIg, but typically not to other standard CIDP therapies ^[15]. Anti-MAG neuropathy has a variable response and is often managed with hematology-directed therapies ^[25].

Incorrectly labeling a condition as CIDP can delay disease-specific care ^[2]. In conditions like POEMS, a delayed diagnosis can allow the disease to progress significantly, increasing the risk of severe disability ^[24]. Additionally, taking ineffective immune therapies exposes patients to unnecessary risks—such as infusion reactions, blood clots, or kidney issues with IVIg, and widespread side effects from high-dose corticosteroids ^[26].

Quick Comparison Table

(Note: The table above highlights typical patterns, but exceptions exist for every condition.)